

PEI Pharmacare Bulletin

Issue (2019 - 10)

November 12, 2019

NEW PRODUCT(S) ADDED TO THE PEI PHARMACARE FORMULARY (EFFECTIVE DATE: November 25, 2019)

| Product (Generic name) | Product (Brand name) | Strength | Dosage Form | DIN | MFR |
|---|----------------------|-----------------------|-------------|----------|-----|
| Emtricitabine/rilpivirine/ tenofovir alafenamide | Odefsey | 200 mg/25 mg/25 mg | Tablet | 02461463 | GIL |
| Criteria | Open benefit | | | | |
| Program Eligibility | AIDS/HIV Program | | | | |

| Product (Generic name) | Product (Brand name) | Strength | Dosage Form | DIN | MFR |
|---|---|----------------------------|------------------------------|----------|-----|
| Fluticasone/umeclidinium/ vilanterol | Trelegy Ellipta | 100 mcg/62.5 mcg/25 mcg | Dry powder for inhalation | 02474522 | GSK |
| Criteria | Combination therapy with LABA/LAAC/ICS will be considered for patients with Chronic Obstructive Pulmonary Disease (COPD) who experience inadequate control (persistent symptoms or experiencing 2 or more exacerbations of COPD in the previous year requiring treatment with antibiotics and/or systemic corticosteroids or at least 1 exacerbation requiring hospitalization) while being treated with a LABA/LAAC combination for at least two months. | | | | |
| Program Eligibility | Family Health Benefit Drug Program, Financial Assistance Program, Seniors Drug Program, Nursing Home Program, Catastrophic Drug Program | | | | |

CRITERIA CHANGE (EFFECTIVE DATE: November 25, 2019)

| Product (Generic name) | Product (Brand name) | Strength | Dosage Form | DIN | MFR |
|------------------------|---|----------|-------------------|----------|-----|
| Denosumab | Prolia | 60 mg/ml | Prefilled Syringe | 02343541 | AMG |
| Criteria | <p>The Special Authorization Criteria for Prolia has been updated to the following: For the treatment of osteoporosis in postmenopausal women and in men who meet the following criteria:</p> <ul style="list-style-type: none"> o Have a contraindication to oral bisphosphonates; and o High risk for fracture, or refractory or intolerant to other available osteoporosis therapies. <p>Clinical Notes:</p> <ul style="list-style-type: none"> • Refractory is defined as a fragility fracture or evidence of a decline in bone mineral density below pre-treatment baseline levels, despite adherence for one year to other available osteoporosis therapies. • High fracture risk is defined as: <ul style="list-style-type: none"> o Moderate 10-year fracture risk (10% to 20%) as defined by the Canadian Association of Radiologists and Osteoporosis Canada (CAROC) tool or the World Health Organization's Fracture Risk Assessment (FRAX) tool with a prior fragility fracture; or o High 10-year fracture risk ($\geq 20\%$) as defined by the CAROC or FRAX tool. | | | | |
| Program Eligibility | Family Health Benefit Drug Program, Financial Assistance Program, Seniors Drug Program, Nursing Home Program, Catastrophic Drug Program | | | | |

NOTICES

The following products have been removed from PEI Pharmacare Drug Programs, and will no longer be eligible for reimbursement 30 days from this notice (**effective December 12, 2019**):

Adefovir 10 mg tablets

Levofloxacin 750 mg tablets

Vitamin C 500mg tablets

Acyclovir (Zovirax) Cream & Ointment